Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Canopy Growth Corp (CGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Canopy Growth Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Canopy Growth Corp trades at $0.96 (market cap $404.40M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 11.1× Canopy Growth Corp's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | CGC | |
|---|---|---|
Market Cap | $4.49B | $404.40M |
Sector | Health | Health |
52-Week High | $28.06 | $1.92 |
52-Week Low | $20.06 | $0.86 |
Enterprise Value | $3.69B | $343.85M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CGC trades at $0.95, down 5% on the day, with a bearish technical signal and negative earnings momentum after recent quarterly misses. The company reported a net loss of $598.12 million in 2025, with a net income margin of -222.36%, though revenue trends show some stabilization. Cash flow remains negative, and the stock faces Nasdaq listing compliance risks due to its low price, with news highlighting potential for a reverse stock split.
The outlook is highly speculative with significant operational and financial risks. While valuation ratios like P/S of 1.44 and P/B of 0.83 appear modest, persistent losses and high debt levels overshadow any near-term upside. Investor sentiment is mixed among analysts, with a slight hold bias, but the path to profitability remains uncertain amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
